CERTIFICATE

IMPACT FACTOR 2021

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Clinical Effects of EGFR Inhibitors on EGFR exon19 and 21 Mutationsin Lung Cancer

Author: 
He-Ping Lin, Xiao-Diao Zhang, Xi-xian Lou and Chang Cai,
Subject Area: 
Health Sciences
Abstract: 

Objective: This study is to investigate the clinical efficacy of EGFR inhibitors on mutations in lung cancer patients with EGFR 19 and 21 exons. Methods: A total of 178 lung cancer patients were selected from January 2012 to September 2016 in this study and their EGFR mutations were analyzed by Real-time PCR. Then the patients were divided into Exon 19 group (n = 89) and Exon 21 group (n = 89) according to EGFR mutation status, and being treated with EGFR inhibitor erlotinib. Finally, the clinical efficacy and safety of the two groups were analyzed. Results: The average age of patients in Exon 19 group was lower than that of Exon21 group (P <0.05). The response Rate (RR) of the Exon19 group was 51.69%, while the RR of the Exon21 group was 48.31% (P> 0.05). The median overall survival (OS) were 56.00 months (95CI%: 54.054,57.946) and 49.00 months(95CI%: 47.682, 50.316)in the Exon 19 group and Exon21 group respectively. The median Progression-free Survival (PFS) were 50.00 (95CI%: 47.529,52.471) and 41.00 (95CI%: 38.738,43.262)in the Exon 19 group and Exon21 group respectively. Furthermore, the incidence of adverse reactions was similar between the two groups (P> 0.05). Conclusion: Lung cancer patients with EGFR 19 exon mutation are younger than those with EGFR 21 exon mutations, which may get more benefits from EGFR inhibitor therapy.

PDF file: 

CALL FOR PAPERS

 

ONLINE PAYPAL PAYMENT

IJMCE RECOMMENDATION

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

 

EDITORIAL BOARD

Dr. Swamy KRM
India
Dr. Abdul Hannan A.M.S
Saudi Arabia.
Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran